Stockscreener 앱 받기
0.6768
4.95%
0.0319
시간 외 거래:
.67
-0.0068
-1.00%
전일 마감가:
$0.6449
열려 있는:
$0.63
하루 거래량:
221.54K
Relative Volume:
0.46
시가총액:
$27.16M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.0952
EPS:
-7.11
순현금흐름:
$-155.03M
1주 성능:
-4.78%
1개월 성능:
+15.73%
6개월 성능:
-73.67%
1년 성능:
-85.41%
1일 변동 폭
$0.63
$0.6801
1주일 범위
$0.6201
$0.83
52주 변동 폭
$0.505
$5.6199
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - Yahoo Finance
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
BioXcel Therapeutics reports executive transition - Investing.com India
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com Australia
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
BTAI Shares Experience Decline in Value - Knox Daily
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
The Potential Rise in the Price of BioXcel Therapeutics Inc (BTAI) following insiders activity - Knox Daily
BioXcel Therapeutics Inc: Weathering Stock Market Storms with 24.56M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: BioXcel Therapeutics Inc (BTAI) - SETE News
BioXcel Therapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
BioXcel Therapeutics stock hits 52-week low at $0.53 - Investing.com
BTAI underperforms with a -2.28 decrease in share price - US Post News
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
Is it a good time to sell Xcel Energy, Inc. [XEL] shares after an insider sold 2,041 shares? - Knox Daily
Blair William & Co. IL Has $2.01 Million Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal
Gaining Ground: BioXcel Therapeutics Inc (BTAI) Closes Lower at 0.58, Down -12.13 - The Dwinnex
Charting the Course: BioXcel Therapeutics Inc’s BTAI Stock Prospects - The InvestChronicle
Xcel Energy Inc. (NASDAQ:XEL) Shares Acquired by Sei Investments Co. - Defense World
Gabelli Funds LLC Sells 12,283 Shares of Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlackSky target adjusted to $15 from $2.50 at H.C. Wainwright - TipRanks
Summit Trail Advisors LLC Boosts Stock Position in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
BlueLinx Holdings Inc. (NYSE:BXC) Shares Purchased by Massachusetts Financial Services Co. MA - Defense World
BioXcel Therapeutics faces Nasdaq delisting risk over share price - Investing.com India
BioXcel Therapeutics faces Nasdaq delisting risk over share price By Investing.com - Investing.com Canada
Meiji Yasuda Asset Management Co Ltd. Has $1.13 Million Holdings in Xcel Energy Inc. (NASDAQ:XEL) - Defense World
New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):